Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Endovascular Thrombectomy in Patients With Cancer and Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.

Created on 23 Oct 2026

Authors

Nooruldeen H Ali Al-Khafaji, Ali K Al-Shalchy

Published in

Cureus. Volume 18. Issue 9. Pages e116605. Epub Sep 20, 2026.

Abstract

Patients with cancer and acute ischemic stroke are underrepresented in randomized thrombectomy trials, and the safety and effectiveness of endovascular thrombectomy (EVT) in this population remain uncertain. We systematically reviewed clinical, procedural, and safety outcomes of EVT in cancer patients compared to non-cancer controls. Searches of PubMed, Scopus, and the Cochrane Library identified 10 observational studies. Meta-analyses summarized outcomes within cancer groups, while comparative analyses calculated risk differences (RDs) as cancer minus control. Bias was assessed using the ROBINS-I (Risk of Bias In Non-randomized Studies of Interventions) tool. Among cancer patients undergoing EVT, the pooled success rate for recanalization was 77.1% (95% CI, 71.2%-83.0%). Symptomatic intracranial hemorrhage (sICH) occurred in 4.5% (95% CI, 2.6%-6.5%). A favorable 90-day functional outcome (modified Rankin Scale (mRS) ≤2) was seen in 26.8% (95% CI, 20.6%-32.9%), with 39.4% (95% CI, 31.6%-47.2%) dying within 90 days. Comparative analyses showed that cancer patients were significantly less likely to attain mRS ≤2 at 90 days (RD, -0.170; 95% CI, -0.223 to -0.116; I² = 23.4%) and had higher 90-day mortality (RD, 0.234; 95% CI, 0.168 to 0.300; I² = 45.1%). No significant differences were found for successful recanalization (RD, -0.033; 95% CI, -0.083 to 0.016; I² = 31.5%) or sICH (RD, -0.001; 95% CI, -0.020 to 0.018; I² = 0%). Sensitivity analyses excluding high-bias studies produced similar results. EVT can yield high recanalization rates with low sICH risk in cancer patients; however, they show poorer functional recovery and higher 90-day mortality than controls. These results emphasize the need for personalized treatment considering both stroke and cancer prognosis.

PMID:
42904270
Bibliographic data and abstract were imported from PubMed on 23 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 17
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement